Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionRafferty Asset Management, LLC
Latest Disclosed Ownership152,433 shares
Latest Disclosed Value $ 4,528,784
Rafferty Asset Management, LLC reports 9.91% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Rafferty Asset Management, LLC filed a 13F-HR form disclosing ownership of 152,433 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $4,528,784 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 169,208 shares of Travere Therapeutics, Inc.. This represents a change in shares of -9.91% during the quarter. The current value of the position is $6,889,972 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 152,433 -16,775 -9.91 4,529 -29.96 0.0184
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 169,208 78,958 87.49 6,465 199.86 0.0223
2025-11-12 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 90,250 -33,604 -27.13 2,157 17.62 0.0070
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 123,854 -21,167 -14.60 1,833 -29.45 0.0060
2025-05-14 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 145,021 -31,404 -17.80 2,599 -15.46 0.0111
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 176,425 84,654 92.24 3,073 139.52 0.0109
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 91,771 -90,521 -49.66 1,284 -14.35 0.0044
2024-08-13 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 182,292 -412,940 -69.37 1,498 -67.36 0.0056
2024-05-13 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 595,232 166,071 38.70 4,589 18.95 0.0171
2024-02-13 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 429,161 67,168 18.56 3,858 19.22 0.0163
2023-11-13 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 361,993 -136,259 -27.35 3,236 -57.72 0.0190
2023-08-11 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 498,252 171,782 52.62 7,653 4.24 0.0431
2023-05-11 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 326,470 7,016 2.20 7,342 9.29 0.0498
2023-02-13 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 319,454 113,687 55.25 6,718 32.50 0.0562
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 205,767 72,542 54.45 5,070 57.06 0.0540
2022-08-12 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 133,225 -28,018 -17.38 3,228 -22.31 0.0297
2022-05-13 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 161,243 -12,043 -6.95 4,155 -22.76 0.0246
2022-02-10 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 173,286 73,364 73.42 5,379 122.00 0.0283
2021-11-10 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 99,922 -34,739 -25.80 2,423 23.31 0.0166
2021-08-10 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 134,661 36,783 37.58 1,965 -19.60 0.0124
2021-05-10 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 97,878 86,909 792.31 2,444 717.39 0.0167
2021-02-10 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 10,969 -29,575 -72.95 299 -60.03 0.0029
2020-11-13 2020-09-30 13F RETROPHIN COM 761299106 40,544 23,314 135.31 748 112.50 0.0090
2020-08-07 2020-06-30 13F RETROPHIN COM 761299106 17,230 17,230 352 0.0050
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 0 -46,425 -100.00 0 -100.00
2020-02-10 2019-12-31 13F RETROPHIN COM 761299106 46,425 -83,503 -64.27 659 -56.24 0.0101
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 129,928 63,622 95.95 1,506 13.06 0.0236
2019-08-09 2019-06-30 13F RETROPHIN COM 761299106 66,306 8,237 14.18 1,332 1.37 0.0234
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 58,069 58,069 1,314 0.0211
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.